The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Robotic surgery has been expanding in Scotland since it was first introduced in Grampian in 2015. Companies such as Versius, ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

Diatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA ("Merck"). The collaboration aims to improve patient access to RAS ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

The Bombay High Court has directed the Centre and State to respond to a PIL requesting cancer warning labels on alcohol ...